secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2026-05-12T11:39:12+00:00
Accession:  0001193125-26-218198
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics Q1 net loss $7.2M; cash $50.7M; FDA Fast Track for COYA 302 in ALS
--------------------------------------------------------------------------------

- Net loss $7.2M vs $7.3M YoY; R&D expense fell to $4.1M (down $1.1M), G&A rose to $3.4M (up $1.1M).
- Cash and cash equivalents $50.7M as of March 31, 2026.
- FDA granted Fast Track Designation to COYA 302 for ALS on March 11, 2026.
- ALSTARS Phase 2 trial now in full recruitment; topline readout expected Q1 2027.
- Completed $11.1M private placement led by Dr. Reddy's ($10M) and Greenlight Capital ($1.1M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526218198/0001193125-26-218198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526218198/coya-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer